ClinicalTrials.gov
public full text
Public Domain
Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients
The primary objective is to evaluate the efficacy/safety of lazertinib and to explore the resistance mechanism of lazertinib as first-line in patients with NSCLC harboring activating EGFR mutations.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations#245521
- Treatment sequences in EGFR mutant advanced NSCLC#923029
- PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC#67895
- Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance#834144
- Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR#886519
Record · ID 868062
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive